Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-1041

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment ; volume:70 ; number:1 ; day:6 ; month:10 ; year:2013 ; pages:29-35 ; date:1.2014
European journal of clinical pharmacology ; 70, Heft 1 (6.10.2013), 29-35, 1.2014

Creator: Weller, Stephen
Borland, Julie
Chen, Shuguang
Johnson, Mark
Savina, Paul
Wynne, Brian
Wajima, Toshihiro
Peppercorn, Amanda F.
Piscitelli, Stephen C.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00228-013-1590-9

URN: urn:nbn:de:101:1-2019101402490721770367

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Weller, Stephen
Borland, Julie
Chen, Shuguang
Johnson, Mark
Savina, Paul
Wynne, Brian
Wajima, Toshihiro
Peppercorn, Amanda F.
Piscitelli, Stephen C.
SpringerLink (Online service)

Other Objects (12)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

Schriftgut

DR 137: Seronegative Spondylarthritiden

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

Schriftgut

DR 137: Seronegative Spondylarthritiden

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

Schriftgut

DR 137: Seronegative Spondylarthritiden

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

DR 137: Seronegative Spondylarthritiden

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

DR 137: Seronegative Spondylarthritiden

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

DR 137: Seronegative Spondylarthritiden

Related objects

Reset password